Evidence map›Paper›PMID 37198593›Full record

ArticleJournal of translational medicine2023

Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells.

Yafei Zhang, Bingqian Yang, Chengwei Tu, Yifan Ping, Shuhong Chen, Tong Wu, Zheyu Zhao, Yixin Mao, Zhan Yang, Zelin Cao and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Yafei Zhang *School and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Bingqian Yang *School and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Chengwei Tu *The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Yifan PingSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Shuhong ChenSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Tong WuSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Zheyu ZhaoSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Yixin MaoSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China.
Zhan YangSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Zelin CaoSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Jianmin LiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Kate HuangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Xi DingThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China.
Gang WuDepartment of Oral and Maxillofacial Surgery/Pathology, Amsterdam UMC and Academic Center for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam (VU), Amsterdam Movement Science (AMS), Amsterdam, The Netherlands.
Peng ZouSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China. zoupeng123@163.com.
Zhennan DengSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China. dengzhennan@wmu.edu.cn.
Xiaoyu SunSchool and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China. sunxyu198912@163.com.ORCID 0000-0003-4494-6749
Wenzhou Medical University · CNAcademic Center for Dentistry Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral squamous cell carcinoma (OSCC) is one of the most prevalent and fatal oral cancers. Mitochondria-targeting therapies represent promising strategies against various cancers, but their applications in treating OSCC are limited. Alantolactone (ALT) possesses anticancer properties and also regulates mitochondrial events. In this study, we explored the effects of ALT on OSCC and the related mechanisms.

methodsThe OSCC cells were treated with varying concentrations and duration of ALT and N-Acetyl-L-cysteine (NAC). The cell viability and colony formation were assessed. The apoptotic rate was evaluated by flow cytometry with Annexin V-FITC/PI double staining. We used DCFH-DA and flow cytometry to detect reactive oxygen species (ROS) production and DAF-FM DA to investigate reactive nitrogen species (RNS) level. Mitochondrial function was reflected by mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and ATP levels. KEGG enrichment analyses determined the mitochondrial-related hub genes involved in OSCC progression. Dynamin-related protein 1 (Drp1) overexpression plasmids were further transfected into the cells to analyze the role of Drp1 in OSCC progression. Immunohistochemistry staining and western blot verified the expression of the protein.

resultsALT exerted anti-proliferative and pro-apoptosis effects on OSCC cells. Mechanistically, ALT elicited cell injury by promoting ROS production, mitochondrial membrane depolarization, and ATP depletion, which were reversed by NAC. Bioinformatics analysis showed that Drp1 played a crucial role in OSCC progression. OSCC patients with low Drp1 expression had a higher survival rate. The OSCC cancer tissues presented higher phosphorylated-Drp1 and Drp1 levels than the normal tissues. The results further showed that ALT suppressed Drp1 phosphorylation in OSCC cells. Moreover, Drp1 overexpression abolished the reduced Drp1 phosphorylation by ALT and promoted the cell viability of ALT-treated cells. Drp1 overexpression also reversed the mitochondrial dysfunction induced by ALT, with decreased ROS production, and increased mitochondrial membrane potential and ATP level.

conclusionsALT inhibited proliferation and promoted apoptosis of oral squamous cell carcinoma cells via impairment of mitochondrial homeostasis and regulation of Drp1. The results provide a solid basis for ALT as a therapeutic candidate for treating OSCC, with Drp1 being a novel therapeutic target in treating OSCC.

Indexed as

DynaminsMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckAdenosine TriphosphateApoptosisCell Line, TumorDown-RegulationHumansLactonesMitochondriaPhosphorylationReactive Oxygen SpeciesSesquiterpenes, EudesmaneAdenosine TriphosphatealantolactoneDNM1L protein, humanDynaminsLactonesReactive Oxygen SpeciesSesquiterpenes, EudesmaneAlantolactone (ALT)Dynamin-related protein 1 (Drp1)Mitochondrial impairmentOral squamous cell carcinoma (OSCC)Reactive oxygen species (ROS)

Identifiers

PMID37198593
PMCPMC10193726
OpenAlexW4376866159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.